SSRI Users With Gene Variant Faced Earlier Heart Valve Surgery — SkimNews
SkimNews Take
Pairing a serotonin gene variant with SSRI-linked valve damage nudges psychiatry toward pre-prescription genotyping, suggesting future antidepressant selection may depend on cardiac-risk DNA panels rather than trial-and-error dosing.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Columbia University researchers, in a multicenter study published in Science Translational Medicine in 2023, found that DMR patients taking SSRIs who carried the "long-long" variant of the 5-HTTLPR gene region underwent mitral valve surgery more often and at younger ages than patients with other variants.
- The team reviewed clinical data from more than 9,000 patients who had undergone mitral valve repair or replacement, alongside 100 mitral valve biopsies, making it one of the largest clinical datasets on this question.
- Giovanni Ferrari, PhD, scientific director of Columbia's Cardiothoracic Research Program, co-led the work with CHOP's Robert J. Levy, MD, with collaborators at the University of Pennsylvania and the Valley Hospital Heart Institute and funding from the National Heart, Lung, and Blood Institute.
- In mouse experiments, animals lacking the SERT gene developed thicker mitral valves, and normal mice given high-dose SSRIs also showed thickened valves, supporting a biological mechanism behind the patient-level association.
- Laboratory work showed mitral valve cells from patients with the "long-long" variant reacted more strongly to serotonin, produced excess collagen, and were more sensitive to fluoxetine than cells carrying other variants.
- The researchers proposed a DNA test for 5-HTTLPR — using a blood sample or mouth swab — to identify DMR patients who may need closer monitoring or earlier surgery, though such testing has not become a standard part of heart valve care.
- Ferrari stressed that SSRIs did not harm healthy valves in the experiments, and the strongest signal appeared only in valves that had already begun to degenerate — meaning the findings do not justify stopping antidepressants without clinical guidance.
Why it matters: If validated in clinical trials, a simple genetic swab could let cardiologists identify the subset of DMR patients on SSRIs who may need earlier surgical intervention — potentially preventing heart failure — but current guidelines still evaluate valve disease without genetic testing, so this remains a research proposal rather than a clinical standard.
Ask SkimNews
